TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.38
−6.67% on the day

The median 12-month analyst price target for Tonix Pharmaceuticals Holding Corp. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$46.2M
Ticker Nerd rank
22/ 100
Median analyst target
$22
Analysts covering
4
Revenue$13.5M+577.9% y/y
Operating income−$41.9M
Net income−$40.6M
Free cash flow−$42.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.9%
1M
−58.8%
YTD
−84.8%
1Y
−84.8%
From 52W high
−88.0%
From 52W low
0.0%
$2
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
22/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
65
Quality
63
Growth
43
Volatility
37
Revisions
34
Issuance
16
Value
11
Momentum
6

Accruals (65): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TNXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26TNXPHigh $56Median $22Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$14
Low
$22
Median
$56
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Oct 2026Canaccord GenuityInitiatesBuy$18
25 June 2026Raymond JamesInitiatesStrong Buy$26
4 May 2026TD CowenInitiatesBuy—
20 Mar 2025Noble Capital MarketsReiteratesOutperform—
22 July 2024Alliance Global PartnersMaintainsBuy—
28 Feb 2024Dawson JamesInitiatesBuy—
1 Aug 2023Alliance Global PartnersMaintainsBuy—
2 June 2023Alliance Global PartnersMaintainsBuy—
12 Jan 2023Alliance Global PartnersReiteratesBuy$6.50
18 Apr 2022Noble Capital MarketsInitiatesOutperform$0.60
31 Aug 2021Alliance Global PartnersMaintainsBuy—
11 Aug 2021Alliance Global PartnersMaintainsBuy—
25 Feb 2021Alliance Global PartnersMaintainsBuy—
18 Nov 2019B. Riley FBRDowngradeNeutral—
18 Nov 2019Cantor FitzgeraldDowngradeHold—
18 Nov 2019Janney CapitalInitiatesBuy—
18 Nov 2019OppenheimerMaintainsOutperform—
18 Nov 2019Roth CapitalUpgradeBuy—
18 Apr 2019Roth CapitalUpgradeBuy—
27 July 2018B. Riley FBRDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TNXP.

Market Radar

This page is one stock. Monday covers all of them.

TNXP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TNXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tonix Pharmaceuticals Holding Corp. returned −84.8% against +6.9% for the S&P 500, dividends included.

TNXP vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26TNXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 64% of US stocks

Price / book
0.2×

Cheaper than 93% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
94.8%

Higher than 98% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−84.1%

Higher than 15% of US stocks

Return on assets
−47.4%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tonix Pharmaceuticals Holding Corp. has a market value of $46.2M.

  • Revenue in the twelve months to 30 June 2026: $29.1M. The latest quarter grew 577.9% year on year.

  • Net income over the same four quarters: −$159.7M, a −548.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$12.94.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Tonix Pharmaceuticals Holding Corp. spent $7.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 16.8M.

  • Tonix Pharmaceuticals Holding Corp. employs 142 people — $205K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

TNXP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
MISTMilestone Pharmaceuticals, Inc.$46.2M29
HOWLWerewolf Therapeutics, Inc.$46.0M90
RNXTRenovoRx, Inc.$45.5M34
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
APLMApollomics, Inc.$45.3M9
ONCYOncolytics Biotech, Inc.$47.7M38

Take a look at TNXP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TNXP

What is the TNXP stock price forecast for 2026-2027?

The median 12-month analyst price target for Tonix Pharmaceuticals Holding Corp. is $22, with estimates ranging from $14 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNXP stock a buy right now?

Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNXP?

As at 21 Nov 2026, Tonix Pharmaceuticals Holding Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (65 of 100).

Will TNXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $22, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNXP stock forecast for 2030?

No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $56 over the next 12 months.

How has TNXP stock performed over the past year?

Tonix Pharmaceuticals Holding Corp. returned -84.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care.

Company

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care. The company’s pipeline includes programs aimed at neurological, infectious, and immune-related diseases, reflecting a broad research and development platform built around small molecules and biologics. Tonix Pharmaceuticals Holding Corp. serves the U.S. healthcare market through a combination of commercial products, clinical development programs, and disease-focused collaborations. Its role in the financial market is defined by its position as a commercial-stage biotechnology business with a diversified therapeutic portfolio and ongoing pipeline activity.

CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com